Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

MLA

Jordi Rodon Ahnert, et al. “Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.” Advances in Therapy, vol. 38, July 2021, pp. 4581–91. EBSCOhost, https://doi.org/10.1007/s12325-021-01807-6.

APA

Jordi Rodon Ahnert, Bonnie S. Glisson, Luana Guimarães Sousa, Michael Ka Keu Wong, Sarina Anne Piha-Paul, Dipti Jain, Filip Janku, Apostolia Maria Tsimberidou, Renata Ferrarotto, Charles Lu, Bettzy Stephen, Diana Bell, Aung Naing, George R. Blumenschein, J. Jack Lee, Shubham Pant, Yun Qing, Diana Kaya, & Funda Meric-Bernstam. (2021). Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Advances in Therapy, 38, 4581–4591. https://doi.org/10.1007/s12325-021-01807-6

Chicago

Jordi Rodon Ahnert, Bonnie S. Glisson, Luana Guimarães Sousa, Michael Ka Keu Wong, Sarina Anne Piha-Paul, Dipti Jain, Filip Janku, et al. 2021. “Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.” Advances in Therapy 38 (July): 4581–91. doi:10.1007/s12325-021-01807-6.